Role of bioactive lipid isoprostanes in early diagnosis of inflammatory conditions
Reference number | |
Coordinator | Umeå universitet - Kemiska institutionen |
Funding from Vinnova | SEK 21 921 |
Project duration | July 2015 - September 2015 |
Status | Completed |
Important results from the project
We propose to establish a new method for isoprostanes and develop a new product which later can be used to identify new biomarkers at an early stage of inflammation in humans.
Expected long term effects
The expected outcome is to 1) develop a robust method for detection of isoprostanes bio-markers of inflammatory conditions at an early stage. 2) validate and apply this method to animal models of inflammatory disease and 3) adapt the method to a product intended for the Swedish and Chinese market.
Approach and implementation
The purpose of the current planning phase of the project was to follow up on a previous visit to Umea by Dr. Wang at the Metaboss Technology company, China for discussions about the collaboration and feasibility of the proposed project. We polished the role of each party in accomplishing the project and defined our subsidiary goals and deliverables more clearly. We expected to develop a product for isoprostane detection within the stipulated project period of 2.5 years.